Prelude Therapeutics Inc (PRLD NASDAQ) stock market data APIs
$2.1387
0.01(0.5%)
as of February 9, 2026
Try our APIs with
free plan!
Prelude Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prev. Close
2.1387
Open
2.1493
High
2.1533
Low
2.0293
52 wk Range
0.6101-4.22
Market Cap
135 M
Shares Outstanding
43 765 K
Revenue
10 500 K
EPS
-0.26
Beta
0.873
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Prelude Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Prelude Therapeutics Inc data using free add-ons & libraries
Get Prelude Therapeutics Inc Fundamental Data
Prelude Therapeutics Inc Fundamental data includes:
- Net Revenue: 10 500 K
- EBITDA: -119 267 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.3697
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Prelude Therapeutics Inc News
New
Definitive Healthcare And 2 Other Promising Penny Stocks
As the U.S. stock market edges higher with the S&P 500 reaching new milestones, investors are keenly watching for signals from the Federal Reserve and major tech earnings that could influence future t...
December 2025's Intriguing Stocks Priced Below Estimated Value
As major stock indexes in the United States show mixed performance following two consecutive sessions of losses, investors are keeping a close eye on market movements and economic indicators. In this ...
Celsius Holdings Among 3 Value Stocks Trading Below Estimated Worth
As the United States market kicks off a holiday-shortened week with major stock indexes closing lower, investors are closely watching sectors like technology and precious metals, which have recently e...
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic...
Get Prelude Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
